tradingkey.logo

BRIEF-Immunitybio To Submit BLA In 2025 Based On Quilt 3.055 Data

ReutersJan 29, 2025 1:32 PM

- Immunitybio Inc IBRX.O:

  • IMMUNITYBIO ANNOUNCES COLLABORATION WITH BEIGENE ON CONFIRMATORY PHASE 3 TRIAL OF ANKTIVA® AND PD-1 CHECKPOINT INHIBITOR COMBINATION IN NON-SMALL CELL LUNG CANCER

  • IMMUNITYBIO INC - TO SUBMIT BLA IN 2025 BASED ON QUILT 3.055 DATA

  • IMMUNITYBIO INC - PATENT FOR ANKTIVA AND CPI COMBINATIONS EXTENDS TO 2035

Source text: ID:nBw6YYSLka

Further company coverage: IBRX.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI